SEC Form 4 · accession 0001840706-26-000293
SOPHiA GENETICS SA · SOPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Manuela Valente
Officer — Chief People Officer
Period of report
Aug 19, 2026
Accepted (ET)
Aug 21, 2026 · 4:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001840706
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 19, 2026 | M | 10,000 | $3.20 | A | 220,450 | D | |
| Ordinary SharesF1,F2 | Aug 19, 2026 | S | 10,000 | $7.9439 | D | 210,450 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1,F4,F3 | $3.20 | Aug 19, 2026 | M | 10,000 | D | — | Jan 1, 2029 | Ordinary Shares | 10,000 | 0 | D |
Explanation of responses
- F1Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c).
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.90 to $8.01, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The share options are fully vested and exercisable.
- F4Following the transaction reported on this line, the Reporting Person holds an aggregate total of 554, 276 derivative share options across all remaining grant tranches with varying exercise prices.